The data were, however, not compatible with a protective intention-to-treat effect. They concluded: Randomized trials using MALO as an outcome might be unfeasible, motivating further large observational studies using appropriate methodology to further delineate the effect of GLP1 agonists on the risk of MALO, complementing future phase 3 trials of GLP1 agonists.
The honest cautions apply to the whole compounded-GLP-1 category in 2026: the products aren't FDA-approved, the regulatory environment is tightening, and the refund and cancellation terms deserve careful reading before you pay
The healthcare provider or your doctor may also consider reassessing the dosage or exploring alternative medications or therapies
Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy
Since then, the drugs slew of uses has kept growing
Take my FREE Nutrition Survey to find out which supplements match your specific health concerns no guessing, no wasted money